Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

We have 5 antipsychotic PhD Projects, Programmes & Scholarships

Discipline

Discipline

All disciplines

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


antipsychotic PhD Projects, Programmes & Scholarships

We have 5 antipsychotic PhD Projects, Programmes & Scholarships

Shared decision making and psychosis – whose voice counts in the conversations about stopping or reducing antipsychotic medication

Prescribing antipsychotics has increased steadily in England over the last decade. For serious mental health conditions like schizophrenia, they are prescribed with the view of keeping the patient on them indefinitely. Read more

Molecular characterisation of a novel transporter for the atypical antipsychotic clozapine

Schizophrenia is a severe psychiatric illness affecting about 24 million people worldwide. Schizophrenia can have a devastating effect on a patient’s life and is associated with increased mortality, with life expectancy reduced on average by 15 years compared to that of the general population. Read more

Integrated omics approach to psychiatric disorders

  Research Group: Chemistry and Biosciences
In psychiatry, the selection of antipsychotics and antidepressants is led by a trial-and-error approach. The prescribing of these medications is complicated by sub-optimal efficacy and high rates of adverse drug reactions (ADRs). Read more

Biological rhythms and the dopamine system in cognitive dysfunction

  Research Group: Pharmacology and Experimental Therapeutics
Psychiatric disorders such as schizophrenia are associated with metabolic syndrome, obesity and diabetes. Schizophrenia affects 1.1% of the population and although not the most common psychiatric condition it is arguably the most severe and debilitating. Read more

Developing biodegradable long acting drug delivery systems for the treatment of chronic conditions

Non-adherence to treatment costs the NHS more than £500M each year. Adherence is especially important when treating patients with chronic conditions that require lifetime pharmacological treatment, such as schizophrenia, Parkinson’s disease, HIV and Alzheimer’s disease. Read more
  • 1

Filtering Results